Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 214 current clinical trials in our China register. 153 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Venetoclax, Cytarabine and Rituximab. The most-studied condition is Treatment.

ClinicalTrials.gov trials by status

Recruiting15371%
Not yet open3416%
Active, closed2210%
By invitation52%

Trials by phase

Phase 29143%
Not applicable3114%
Phase 12612%
Observational2311%
Phase 1/2188%
Phase EARLY_PHASE1105%
Phase 363%
Phase 452%
Phase 2/342%

Clinical trials sponsored by Institute of Hematology & Blood Diseases Hospital, China

214 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma NCT05958719 · Peripheral T Cell Lymphoma, Epigenetic Repression Drugs: Azacitidine, Chidamide, Liposomal mitoxantrone	Phase 2	Recruiting	2023-03	China
Cohort of Nursing Homes NCT07249086 · ClinicalTrials.gov ↗ · Health Status	Observational	Recruiting	2023-11	China
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic Drug: Olverembatinib	Phase 3	Recruiting	2025-03	China
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia NCT07019766 · ClinicalTrials.gov ↗ · T-LGL Leukemia, NK-LGL Leukemia	Observational	Recruiting	2000-01	China
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia NCT05199909 · ClinicalTrials.gov ↗ · Antiphospholipid Syndrome, Thrombocytopenia, Treatment Drug: Zanubrutinib	Phase 2	Recruiting	2022-01	China
Eltrombopag for Chemotherapy-induced Thrombocytopenia NCT04600960 · ClinicalTrials.gov ↗ · Chemotherapy-induced Thrombocytopenia, Eltrombopag Drug: Eltrombopag	Phase 2	Recruiting	2020-12	China
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880 · ClinicalTrials.gov ↗ · FLT3 Gene Mutation, AML Drugs: Cytarabine, Gilteritinib, Venetoclax	Phase 1/2	Recruiting	2024-10	China
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma NCT07555470 · ClinicalTrials.gov ↗ · Follicular Lymphoma Drugs: Mosunetuzumab, Zeprumetostat	Phase 2	Recruiting	2026-04	China
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation NCT07297576 · ClinicalTrials.gov ↗ · ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, MDS (Myelodysplastic Syndrome)	Not applicable	Recruiting	2025-10	China
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT NCT06447090 · ClinicalTrials.gov ↗ · Relapse Acute Myeloid Leukemia Drugs: Cyclophosphamide, Cytarabine, Mitoxantrone Hydrochloride Liposome	Phase 2	Recruiting	2024-04	China
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL NCT07278882 · ClinicalTrials.gov ↗ · Pediatric Acute Leukemia	Not applicable	Recruiting	2025-12	China
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients NCT07169500 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Car-T	Phase 1/2	Recruiting	2025-03	China
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL NCT07441993 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma Drug: Orelabrutinib	Phase 2	Recruiting	2026-01	China
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes NCT05925504 · ClinicalTrials.gov ↗ · Lower Risk MDS Per IPSS-R Drug: Luspatercept	Phase 2	Recruiting	2023-07	China
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL NCT07106723 · ClinicalTrials.gov ↗ · CD7 Positive, T - Cell Lymphoma Drug: ASCT	Phase 2	Recruiting	2025-06	China
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550 · ClinicalTrials.gov ↗ · Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia	Phase 2	Recruiting	2024-08	China
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia NCT07188740 · ClinicalTrials.gov ↗ · DNMT3A Gene Mutation Drug: Metformin	Phase 1	Recruiting	2026-08	China
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients NCT06880380 · ClinicalTrials.gov ↗ · HIV Infected Individuals, HIV	Phase 1	Recruiting	2025-09	China
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia NCT06281327 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment Drug: Avatrombopag	Phase 2	Recruiting	2024-03	China
Herombopag for Chemotherapy-induced Thrombocytopenia NCT05236582 · ClinicalTrials.gov ↗ · Chemotherapy-induced Thrombocytopenia, Herombopag Drug: Herombopag	Phase 2	Recruiting	2022-03	China
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage NCT04440267 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage Drugs: Cyclophosphamide, Daunorubicin, Dexamethasone	Phase 2	Recruiting	2020-07	China
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy NCT05991336 · ClinicalTrials.gov ↗ · Transfusion-dependent Beta-Thalassemia, Gene Therapy	Observational	Recruiting	2023-06	China
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy NCT07212335 · ClinicalTrials.gov ↗ · Immune Effector Cell Associated Hematotoxicity	Phase EARLY_PHASE1	Recruiting	2025-10	China
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658 · ClinicalTrials.gov ↗ · Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia	Phase 2	Recruiting	2024-12	China
A Study of CT0596 in Plasma Cell Leukemia NCT06988059 · ClinicalTrials.gov ↗ · Plasma Cell Leukemia	Phase EARLY_PHASE1	Recruiting	2025-06	China
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients NCT06918834 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes	Phase 2	Recruiting	2025-07	China
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Observational	Recruiting	2022-11	China
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia NCT07106684 · ClinicalTrials.gov ↗ · Multiple Myeloma, Plasma Cell Leukemia Drugs: Bcma Car-T, GPRC5D/CD3 BiTEs	Phase 2	Recruiting	2025-08	China
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML NCT07304232 · ClinicalTrials.gov ↗ · Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia) Drug: Chidamide	Phase 2	Recruiting	2025-09	China
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma NCT07106671 · ClinicalTrials.gov ↗ · CRS - Cytokine Release Syndrome, Myeloma	Phase 2	Recruiting	2025-08	China
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) NCT07362238 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment Drugs: Daratumumab, Rituximab	Phase 2	Recruiting	2026-03	China
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT06880354 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1	Recruiting	2025-05	China
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia NCT05979363 · ClinicalTrials.gov ↗ · Plasma Cell Leukemia Drug: Anti-BCMA CAR-T	Phase 2	Recruiting	2023-08	China
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia NCT06224257 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large Granular T Lymphocytic Leukemia Drug: Linperlisib	Phase 2	Recruiting	2023-12	China
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) NCT06107582 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia	Observational	Recruiting	2023-11	China
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP NCT06838949 · ClinicalTrials.gov ↗ · Herombopag Drug: Herombopag olamine	Phase 2	Recruiting	2025-03	China
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	2025-01	China
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases NCT07135778 · ClinicalTrials.gov ↗ · Invasive Fungal Disease	Observational	Recruiting	2025-05	China
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228 · ClinicalTrials.gov ↗ · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult Drugs: Olverembatinib, Venetoclax	Not applicable	Recruiting	2024-06	China
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety NCT07185503 · ClinicalTrials.gov ↗ · Mucormycosis in Hematologic Malignancies Drug: Liposomal Amphotericin B	Observational	Recruiting	2025-03	China
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years NCT04890041 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenic Purpura Drug: Tpo-Ra	Not applicable	Recruiting	2021-05	China
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT NCT07126782 · ClinicalTrials.gov ↗ · AML (Acute Myelogenous Leukemia), AML	Phase EARLY_PHASE1	Recruiting	2025-07	China
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL NCT07454226 · ClinicalTrials.gov ↗ · Ph-Like, Acute Lymphoblastic Leukemia Drugs: Blinatumomab, Gecacitinib, Olverembatinib	Not applicable	Recruiting	2026-05	China
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia NCT06613880 · ClinicalTrials.gov ↗ · Aplastic Anemia, TPO Receptor Agonists	Phase 2	Recruiting	2024-10	China
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma NCT07249073 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	2025-03	China
Gene Therapy for Chinese Hemophilia A NCT04728841 · ClinicalTrials.gov ↗ · Hemophilia A, Gene Therapy	Not applicable	Recruiting	2021-03	China
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP) NCT06094881 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment Drug: Obinutuzumab	Phase 2	Recruiting	2023-12	China
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease NCT06793475 · ClinicalTrials.gov ↗ · Extramedullary Multiple Myeloma Drugs: Carfilzomib, Dexamethasone, Thalidomide	Not applicable	Recruiting	2025-04	China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma Drugs: Ara-C, Carboplatin, Cisplatin	Phase 2	Recruiting	2024-05	China
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) NCT07234019 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment Drugs: Daratumumab（Anti-CD38 Monoclonal Antibody）, Rituximab	Phase 2	Recruiting	2026-01	China
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL NCT03980002 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia	Phase 2	Recruiting	2019-05	China
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL NCT07493161 · ClinicalTrials.gov ↗ · Ph+ ALL Drugs: Blinatumomab, Inotuzumab ozogamicin, Olverembatinib	Not applicable	Recruiting	2026-04	China
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) NCT05632380 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	2022-07	China
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients NCT06238908 · ClinicalTrials.gov ↗ · Hemophilia A	Phase EARLY_PHASE1	Recruiting	2024-01	China
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies NCT04993885 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Autoantibodies, Evan Syndrome Drug: Avatrombopag	Phase 2	Recruiting	2021-09	China
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution. NCT06208137 · ClinicalTrials.gov ↗ · Transplant-Related Disorder	Not applicable	Recruiting	2024-02	China
MRD-positive AML Clinical Study NCT07131059 · ClinicalTrials.gov ↗ · AML, Adult Drugs: Avapritinib, Azacitidine, Cytarabine	Not applicable	Recruiting	2024-05	China
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia NCT07010237 · ClinicalTrials.gov ↗ · Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment	Phase 2	Recruiting	2025-02	China
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia NCT06622694 · ClinicalTrials.gov ↗ · Severe Aplastic Anemia, Relapse, Refractory	Phase 1	Recruiting	2025-06	China
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients NCT07132684 · ClinicalTrials.gov ↗ · AML, Adult Drugs: Azacitidine, Cytarabine, Venetoclax	Phase 3	Recruiting	2025-08	China
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma NCT05913804 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 1	Recruiting	2023-06	China
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 NCT06744504 · ClinicalTrials.gov ↗ · AML, RUNX1-RUNX1T1 Fusion Protein Expression Drugs: Cyclophosphamide, Cytarabine, Daunorubicin	Phase 3	Recruiting	2025-01	China
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults NCT04518475 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP) Drug: Eltrombopag	Phase 4	Recruiting	2020-08	China
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） NCT07406139 · ClinicalTrials.gov ↗ · Hemophilia, Inhibitors	Phase 4	Recruiting	2026-03	China
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. NCT06733610 · ClinicalTrials.gov ↗ · Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells	Phase 1	Recruiting	2024-12	China
Anti-CD38 Antibody Treating Evans Syndrome NCT06014775 · ClinicalTrials.gov ↗ · Evan Syndrome, Treatment	Phase 2	Recruiting	2023-12	China
Reproductive and Mental Health of Patients With Aplastic Anemia NCT06936930 · ClinicalTrials.gov ↗ · Aplastic Anemia, Reproductive Health	Observational	Recruiting	2025-03	China
A Cohort Study on the Association Between the ANS Function and Acute GvHD NCT07374874 · ClinicalTrials.gov ↗ · Transplant-Related Disorder	Observational	Recruiting	2025-12	China
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. NCT05630651 · ClinicalTrials.gov ↗ · Hemophilia B	Not applicable	Recruiting	2023-04	China
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation NCT06792682 · ClinicalTrials.gov ↗ · Poor Graft Function	Phase 1	Recruiting	2025-02	China
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma NCT07261163 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma Drugs: Lenalidomide, Obinutuzumab, Zanubrutinib	Phase 2	Recruiting	2025-12	China
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma	Phase 1	Recruiting	2025-06	China
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy	Phase 1	Recruiting	2025-02	China
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma NCT06745687 · ClinicalTrials.gov ↗ · High Risk Smoldering Multiple Myeloma	Not applicable	Recruiting	2024-12	China
Adverse Effects of ATG/ALG Therapy in Aplastic Anemia NCT07461116 · ClinicalTrials.gov ↗ · Aplastic Anaemia	Observational	Recruiting	2026-02	China
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087 · ClinicalTrials.gov ↗ · SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies Drug: QT-019C	Phase 1	Recruiting	2026-01	China
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A NCT05849740 · ClinicalTrials.gov ↗ · Acquired Hemophilia	Phase 4	Recruiting	2023-05	China
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas NCT06513234 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma	Phase 2	Recruiting	2024-07	China
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML NCT06529250 · ClinicalTrials.gov ↗ · AML Drugs: Cytarabine, Daunorubicin	Not applicable	Recruiting	2024-08	China
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855 · ClinicalTrials.gov ↗ · CML,Blast Phase Drugs: Azacitidine, Olverembatinib, Venetoclax	Phase 1/2	Recruiting	2025-01	China
GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	2024-01	China
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma NCT06793449 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Anti-BCMA CAR-T, ASCT	Phase 2	Recruiting	2025-02	China
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment NCT07585760 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency Drug: Isatuximab	Phase 2	Recruiting	2026-09	China
CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06680388 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase EARLY_PHASE1	Recruiting	2024-11	China
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 · ClinicalTrials.gov ↗ · AML, Acute Myeloid Leukemia Drugs: Azacitidine, Chidamide, Venetoclax	Not applicable	Recruiting	2024-08	China
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia NCT06921980 · ClinicalTrials.gov ↗ · CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function	Observational	Recruiting	2025-02	China
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma NCT07106710 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed Drugs: Bcma Car-T, GPRC5D/CD3 BiTEs	Phase 2	Recruiting	2025-08	China
Newly-diagnosed Pediatric T-cell ALL Protocol NCT06855810 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	Phase 2/3	Recruiting	2025-03	China
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed Drugs: Bcma Car-T, GPRC5D/CD3 BiTEs	Phase 2	Recruiting	2025-08	China
Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia NCT07714512 · ClinicalTrials.gov ↗ · Aplastic Anemia Drug: Isatuximab	Phase 1/2	Recruiting	2026-06	China
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS NCT07578675 · ClinicalTrials.gov ↗ · Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia	Observational	Recruiting	2025-10	China
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia NCT05995054 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment	Phase 2	Recruiting	2023-08	China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma Drugs: 6-mercaptopurine, Cyclophosphamide, Cytarabine	Phase 2	Recruiting	2022-08	China
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) NCT06838962 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment Drug: Daratumumab	Phase 2	Recruiting	2024-08	China
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma NCT07259070 · ClinicalTrials.gov ↗ · DLBCL, CLL, FL	Phase 1/2	Recruiting	2025-11	China
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068 · ClinicalTrials.gov ↗ · T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)	Phase 1/2	Recruiting	2025-06	China
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. NCT06608732 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia	Phase 2	Recruiting	2024-08	China
BCMA CAR-T for Dynamic High-risk Multiple Myeloma NCT06880393 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Anti-BCMA CAR-T	Phase 2	Recruiting	2025-03	China
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry NCT06992076 · ClinicalTrials.gov ↗ · Hemophilia Drug: Marstacimab	Observational	Recruiting	2026-02	China
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL NCT06481241 · ClinicalTrials.gov ↗ · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult Drug: Venetoclax	Not applicable	Recruiting	2024-06	China

Showing the 100 most recently updated of 214 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Institute of Hematology & Blood Diseases Hospital, China trials

93 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 53 more in the trial list above.

Conditions in Institute of Hematology & Blood Diseases Hospital, China trials

206 conditions

Treatment17 Immune Thrombocytopenia15 AML13 Multiple Myeloma12 Acute Myeloid Leukemia10 Multiple Myeloma (MM)5Aplastic Anemia5Autoimmune Hemolytic Anemia5Childhood Leukemia, Acute Lymphoblastic4T-LGL Leukemia4NK-LGL Leukemia4Follicular Lymphoma4Hemophilia4Severe Aplastic Anemia4Hemophilia A4Chemotherapy-induced Thrombocytopenia3Marginal Zone Lymphoma3 Acute Lymphoblastic Leukemia3Transfusion-dependent Beta-Thalassemia3Refractory3Plasma Cell Leukemia3Acute Lymphoblastic Leukemia ALL3Acute Lymphoblastic Leukemia, Adult3AML (Acute Myelogenous Leukemia)3

By trial register

Register	Trials	Recruiting
Clinical trials in China	214	153

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Questions about Institute of Hematology & Blood Diseases Hospital, China trials

How many clinical trials does Institute of Hematology & Blood Diseases Hospital, China sponsor?

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 214 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Institute of Hematology & Blood Diseases Hospital, China trials recruiting?

Yes. 153 of its 214 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Institute of Hematology & Blood Diseases Hospital, China testing?

Its current trials name 93 drugs and biologicals as interventions. The most frequent are Venetoclax (15), Cytarabine (12), Rituximab (9), Azacitidine (8) and Cyclophosphamide (8). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Institute of Hematology & Blood Diseases Hospital, China clinical trials